Symptomatic Orthostatic Hypotension Clinical Trial
Official title:
A Phase 4, Randomized-withdrawal, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension
| Verified date | May 2021 |
| Source | Takeda |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To study the effect of midodrine against the symptoms of orthostatic hypotension
| Status | Completed |
| Enrollment | 98 |
| Est. completion date | November 11, 2013 |
| Est. primary completion date | November 11, 2013 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Male and female subjects must be 18 years of age or older and ambulatory. 2. Females of child-bearing potential (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test. 3. A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl, and has been at a stable dose for at least 3 months. 4. The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out. Exclusion criteria 1. The subject is a pregnant or lactating female. 2. The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit. Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes. 3. Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject. If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study. 4. The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be clinically significant 5. The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406). 6. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures. 7. The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject. 8. Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients. 9. Prior enrollment failure or randomization in this study. 10. History of alcohol abuse or other substance abuse within the last year. |
| Country | Name | City | State |
|---|---|---|---|
| Czechia | Fakultní nemocnice Hradec Králové | Hradec | Králové |
| Czechia | Fakultní nemocnice Ostrava | Ostrava | Poruba |
| Czechia | Fakultní nemocnice v Motole | Praha | |
| Poland | EMC Silesia Sp. z o.o.; NZOZ Szpital Geriatryczny im. Jana Pawla II w Katowicach | Katowice | |
| Poland | Specjalistyczna Praktyka Lekarska Prof. Grzegorz Opala, + satelite site:NZOZ Szpital Avimed Sp. z o.o. | Katowice | |
| Poland | Centrum Medyczne HCP, Lecznictwo Stacjonarne, Oddzial Udarowy | Poznan | |
| Poland | MTZ Clinical Research Sp. z o.o. | Warszawa | |
| Poland | Wojskowy Instytut Medyczny, Klinika Neurologiczna | Warszawa | |
| Slovakia | Neurologické oddelenie FNsP Žilina, Fakultná nemocnica s poliklinikou Žilina | Žilina | |
| Slovakia | Neurologická klinika SZU a UNB, Univerzitná nemocnica Bratislava | Bratislava | |
| Slovakia | Neurologická klinika UN Martin, Univerzitná nemocnica Martin | Martin | |
| Slovakia | Neurologická klinika FN Nitra, Fakultná nemocnica Nitra | Nitra | |
| Slovakia | Neurologické oddelenie, Nemocnica s poliklinikou Spišská Nová Ves, a.s. | Spišská Nová Ves | |
| Slovakia | Neurologické oddelenie FN Trnava, Fakultná nemocnica Trnava | Trnava | |
| United States | PAREXEL International - Baltimore EPCU Harbor Hospital | Baltimore | Maryland |
| United States | Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton | Florida |
| United States | Buffalo Clinical Research Center (BCRC) | Buffalo | New York |
| United States | Cleveland Clinic | Cleveland | Ohio |
| United States | UT South West Medical Center | Dallas | Texas |
| United States | California Clinical Trials Medical Group | Glendale | California |
| United States | Frontage Clinical Services | Hackensack | New Jersey |
| United States | New Orleans Center for Clinical Research - Knoxville | Knoxville | Tennessee |
| United States | Analab Clinical Research Inc | Lenexa | Kansas |
| United States | The Heartbeat Clinic, PA | McKinney | Texas |
| United States | Advance Research Institute Inc | New Port Richey | Florida |
| United States | Columbia University | New York | New York |
| United States | Chicago Medical VA | North Chicago | Illinois |
| United States | Pharmaseek-Burbank | North Hollywood | California |
| United States | Aspen Clinical Research | Orem | Utah |
| United States | DMI Reasearch Inc | Pinellas Park | Florida |
| United States | Parkinson's Disease Treatment Center of Southwest Florida | Port Charlotte | Florida |
| United States | Kidney and Hypertension Center | Roseburg | Oregon |
| Lead Sponsor | Collaborator |
|---|---|
| Shire |
United States, Czechia, Poland, Slovakia,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percent of Subjects Who Failed to Maintain a Response | Failure to maintain a response was defined as any randomized subject that met both criterion 1 and criterion 2 below on Day 16: 1. The Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 score increased by >=4 points compared to baseline. OHSA Item 1 is a dizziness scale that is scored on a range from 0 (no dizziness) to 10 (severe dizziness). A lower score indicates less severe symptoms. 2. There was an increase in the number of syncopal/near syncopal events or severity of events within 15 minutes of standing compared to those observed at baseline. Syncope was defined as a loss of consciousness, and near syncope was defined as a feeling (e.g., dizziness, lightheadedness, feeling faint, feeling as though one would black out) that, without intervention, would lead to a loss of consciousness. | 30 minutes post-dose on Day 16 |